Insider Selling: Celcuity, Inc. (NASDAQ:CELC) Director Sells 100,000 Shares of Stock

Key Points

• Director Transaction: Celcuity, Inc. director David Dalvey sold 100,000 shares at an average price of $43.98, totaling $4.4 million, reducing his ownership by 44.44%.
• Price Performance: Celcuity's stock is currently trading at $40.30, with a one-year range between $7.57 and $46.42, and a market capitalization of $1.53 billion.
• Analyst Ratings: Celcuity has a consensus "Buy" rating with target prices ranging from $29.00 to $60.00, as reported by several investment firms recently.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director David Dalvey sold 100,000 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $43.98, for a total value of $4,398,000.00. Following the sale, the director owned 125,000 shares of the company's stock, valued at $5,497,500. This represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Dalvey also recently made the following trade(s):

• On Monday, July 28th, David Dalvey sold 9,325 shares of Celcuity stock. The shares were sold at an average price of $45.12, for a total value of $420,744.00.

Celcuity Price Performance

Shares of CELC stock traded up $0.74 during trading hours on Friday, hitting $39.91. The company had a trading volume of 1,546,145 shares, compared to its average volume of 537,537. Celcuity, Inc. has a 12 month low of $7.57 and a 12 month high of $46.42. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -13.17 and a beta of 0.45. The firm's fifty day moving average is $14.09 and its 200 day moving average is $11.89. The company has a debt-to-equity ratio of 1.14, a quick ratio of 6.61 and a current ratio of 6.61.

Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. On average, sell-side analysts predict that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. HC Wainwright raised their price target on Celcuity from $27.00 to $50.00 and gave the stock a "buy" rating in a report on Monday. Needham & Company LLC restated a "buy" rating and issued a $29.00 target price on shares of Celcuity in a report on Monday. Leerink Partners increased their price objective on Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday. Finally, Stifel Nicolaus started coverage on Celcuity in a research note on Tuesday, July 1st. They issued a "buy" rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Celcuity presently has an average rating of "Buy" and a consensus target price of $39.20.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Summit Investment Advisors Inc. raised its stake in Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock worth $45,000 after buying an additional 1,132 shares during the period. Aquatic Capital Management LLC acquired a new stake in Celcuity during the 4th quarter worth $50,000. AlphaQuest LLC raised its stake in Celcuity by 176.3% during the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock worth $95,000 after buying an additional 4,522 shares during the period. Focus Financial Network Inc. acquired a new stake in Celcuity during the 1st quarter worth $108,000. Finally, Perkins Capital Management Inc. acquired a new stake in Celcuity during the 1st quarter worth $115,000. Institutional investors and hedge funds own 63.33% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.